Morningstar

argenx SE ARGX Stock

Stock Price as of EUR

Company Profile ARGX

Business Description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Contact
Laarderhoogtweg 25, Amsterdam, NH 1101EB
T +31 107038441
info@argenx.com opens in a new tab
www.argenx.com opens in a new tab
Sector
Healthcare
Industry
Biotechnology
Most Recent Earnings
Jun 30, 2025
Fiscal Year End
Dec 31, 2025
Employees
1,639
As of Dec 31, 2024

Sustainability

ESG Risk Rating Assessment
Highest Controversy Level (1 = Low, 5 = Severe)
None
ESG Risk Rating
24.86
Medium
Negligible
0–9.99
Low
10–19.99
Medium
20–29.99
High
30–39.99
Severe
40+
Highest Controversy Level (1 = Low, 5 = Severe)
Top Material ESG Issues
Product Governance
Overall
Access to Basic Services
Overall
Human Capital
Overall
ESG Risk Rating is as of Sep 03, 2025. Highest Controversy Level is as of Oct 08, 2025. Sustainalytics Subindustry: Biotechnology. Sustainalytics provides Morningstar with company ESG ratings and metrics on a monthly basis and as such, the ratings in Morningstar may not necessarily reflect current Sustainalytics’ scores for the company. For the most up to date rating and more information, please visit: sustainalytics.com/esg-ratings/ opens in a new tab.

© Morningstar 2025. All Rights Reserved. The data and analyses herein do not constitute investment advice; is provided solely for informational purposes; is not an offer to buy/sell a security; and is not warranted to be correct, complete, or accurate. Morningstar is not responsible for any trading decisions, damages or losses resulting from, or related to, the data and analyses or their use. Financial Professionals: This report may not meet all applicable presentation and/or disclosure standards to which you are subject to by a regulator and may need to be supplemented with another report or additional data and/or disclosures. Review carefully before sharing this report and contact your Compliance team with any questions. The ESG-related information, methodologies, tool, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.

©Copyright 2025 Morningstar, Inc. All rights reserved.